Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01305473 · ClinicalTrials.gov registry record

A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite

A clinical trial of Hernia, sponsored by C. R. Bard.

Completed
Registry status
90
Enrollment target
1
Study location

NCT01305473 is a study of Hernia that has completed, run by C. R. Bard. The registered enrollment target is 90 participants, below the 195-participant average among 11 other Hernia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01305473, a study of Hernia, has completed, sponsored by C. R. Bard.

COMPLETED
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

This study will enroll subjects who underwent a laparoscopic ventral hernia repair utilizing Sepramesh at least 12 months before starting in this study. The consented subjects' medical records will be reviewed for evidence of any risk factors of hernia recurrence, procedure time, complications and any documented recurrences. The subjects will be asked to undergo a physical exam to rule out any recurrences that were not documented in the medical records.

Conditions Studied

Study Locations (1)

Ohio

  • Cornerstone Medical Center - Centerville

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2010-08
Est. Completion 2011-02

Sponsor

C. R. Bard

75 total trials

What the Registry Record Tells You About NCT01305473

The ClinicalTrials.gov registry entry for NCT01305473 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 11 other Hernia trials with a reported enrollment target (54% lower). The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hernia appearing as the primary indexed condition, and to 0 interventions.

NCT01305473 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01305473 about?

NCT01305473 is a clinical study titled "A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite". This study will enroll subjects who underwent a laparoscopic ventral hernia repair utilizing Sepramesh at least 12 months before starting in this study. The consented subjects' medical records will be reviewed for evidence of any risk factors of hernia recurrence, procedure time, complications and ...

What is the current status of trial NCT01305473?

This trial is currently completed. The enrollment target is 90 participants. The study started on 2010-08. Estimated completion is 2011-02.

What conditions does trial NCT01305473 study?

This clinical trial studies the following conditions: Hernia.

Who is sponsoring clinical trial NCT01305473?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01305473 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.